MX2023005836A - Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6. - Google Patents

Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6.

Info

Publication number
MX2023005836A
MX2023005836A MX2023005836A MX2023005836A MX2023005836A MX 2023005836 A MX2023005836 A MX 2023005836A MX 2023005836 A MX2023005836 A MX 2023005836A MX 2023005836 A MX2023005836 A MX 2023005836A MX 2023005836 A MX2023005836 A MX 2023005836A
Authority
MX
Mexico
Prior art keywords
deficiency
enpp1
treatment
abcc6
calcification
Prior art date
Application number
MX2023005836A
Other languages
English (en)
Spanish (es)
Inventor
Pedro Huertas
Deborah Wenkert
Original Assignee
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc filed Critical Inozyme Pharma Inc
Publication of MX2023005836A publication Critical patent/MX2023005836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2023005836A 2020-11-19 2021-11-19 Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6. MX2023005836A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063116106P 2020-11-19 2020-11-19
US202063116093P 2020-11-19 2020-11-19
US202063116086P 2020-11-19 2020-11-19
US202163219229P 2021-07-07 2021-07-07
US202163237351P 2021-08-26 2021-08-26
PCT/US2021/060207 WO2022109344A1 (en) 2020-11-19 2021-11-19 Treatment of enpp1 deficiency and abcc6 deficiency

Publications (1)

Publication Number Publication Date
MX2023005836A true MX2023005836A (es) 2023-08-17

Family

ID=81709698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005836A MX2023005836A (es) 2020-11-19 2021-11-19 Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6.

Country Status (11)

Country Link
US (1) US20240181021A1 (https=)
EP (1) EP4247406A4 (https=)
JP (1) JP2024500285A (https=)
KR (1) KR20230123932A (https=)
AU (1) AU2021383830A1 (https=)
CA (1) CA3198957A1 (https=)
CO (1) CO2023007726A2 (https=)
IL (1) IL302954A (https=)
MX (1) MX2023005836A (https=)
TW (1) TW202235100A (https=)
WO (1) WO2022109344A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196820A2 (en) * 2022-04-04 2023-10-12 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency
WO2025042995A1 (en) * 2023-08-22 2025-02-27 Inozyme Pharma, Inc. Treatment of enpp1 deficiency and abcc6 deficiency in children

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP4414028A3 (en) * 2015-05-19 2024-11-27 Yale University Compositions for treating pathological calcification conditions, and methods using same
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3

Also Published As

Publication number Publication date
KR20230123932A (ko) 2023-08-24
EP4247406A4 (en) 2024-10-30
US20240181021A1 (en) 2024-06-06
TW202235100A (zh) 2022-09-16
CO2023007726A2 (es) 2023-07-21
EP4247406A1 (en) 2023-09-27
WO2022109344A1 (en) 2022-05-27
AU2021383830A1 (en) 2023-06-22
CA3198957A1 (en) 2022-05-27
JP2024500285A (ja) 2024-01-09
IL302954A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
MX2023005836A (es) Tratamiento para la deficiencia de enpp1 y la deficiencia de abcc6.
MX2012005151A (es) Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular.
Caplette-Gingras et al. Depression in women with metastatic breast cancer: a review of the literature
MX2021008503A (es) Tratamiento de enfermedades que involucran deficiencia de enpp1 o enpp3.
ATE250566T1 (de) 24-hydroxy vitamin d, deren analogen und verwendungen
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
BRPI0417493A (pt) terapia com toxina botulìnica para distúrbios da pele
AU6173501A (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
WO2007067946A3 (en) Diagnosis and treatment of chronic lymphocytic leukemia (cll)
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
MY158100A (en) 6,9-disubstituted purine derivatives and their use for treating skin
WO2020176654A8 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
Belle et al. Body image in adolescent survivors of childhood cancer: The role of chronic health conditions
WO2006017566A3 (en) Modulation of bio-electrical rhythms via a novel engineering approach
MX2022003811A (es) Determinacion no invasiva de glucosa.
WO2023196820A3 (en) Treatment of enpp1 deficiency and abcc6 deficiency
MX2007013834A (es) Terapias de enfermedades vasculares.
TW202615084A (zh) 治療嬰兒的ｅｎｐｐ１缺乏症和ａｂｃｃ６缺乏症
WO2023129531A3 (en) Methods for diagnosing and/or treating alzheimer's disease
MX2022014733A (es) Composiciones y métodos para inhibir la proliferación de células musculares lisas vasculares.
CO2026002943A2 (es) Tratamiento de la deficiencia de enpp1 y la deficiencia de abcc6 en niños
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
NO20074562L (no) Fremgangsmater for behandling av Parkinsons sykdom